RxDoctor Payments Data

Amanda Wright, DO

Internal Medicine · Homewood, ALNPI 1679065577

Payments from drug & device makers

$5,722in general payments, 2019–2025

Across 337 payments — averaging $16.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$940
  • Lilly USA, LLC$559
  • Novo Nordisk$363
  • Pfizer$312
  • AstraZeneca$311
  • GSK$282
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$5,708100%
  • Entertainment$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,722 in reported general payments places this provider in the 85th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$39,376
Medicare patients
102
Services billed
508

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide156$156,364
MounjaroTirzepatide91$101,325
FarxigaDapagliflozin Propanediol40$48,739
JardianceEmpagliflozin18$21,624
EliquisApixaban16$20,157
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,441
MyrbetriqMirabegron16$12,272
Atorvastatin Calcium216$2,512
SynthroidLevothyroxine Sodium20$2,353
Losartan Potassium169$1,899
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,841
Rosuvastatin Calcium93$1,814
Levothyroxine Sodium122$1,635
Potassium Chloride43$1,150
Amlodipine Besylate188$1,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$363$156,364156 claims
Lilly USA, LLCMounjaro$559$101,32591 claims
AstraZenecaFarxiga$311$48,73940 claims
Boehringer IngelheimJardiance$62$21,62418 claims
PfizerEliquis$312$20,15716 claims
GSKTrelegy Ellipta$282$14,44120 claims
Astellas Pharma US IncMyrbetriq$18$12,27216 claims
AbbVieSynthroid$940$2,35320 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$16$1,635122 claims
Almatica Pharma LLCSertraline Hcl$106$39477 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,533 internal medicine providers in Alabama.

Other internal medicine in Homewood

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →